welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

CureDuchenne Invests in Next Generation Adeno Associated Virus Based Gene Therapy Platform Technology


CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), announced today it has invested in Berkeley, California-based Chameleon Biosciences, Inc. The investment supports the development of a next generation Adeno Associated Virus (AAV) based gene therapy platform called EVADER technology.

Several gene therapies already on the market have shown stunning success in curing disease. Others, like Duchenne, that are in clinical trials are showing great promise. However, current treatment approaches suffer from the fundamental problem that viruses deliver the replacement gene but, as with virus-based vaccines, there is an immune response that prevents repeat dosing.

Chameleon’s EVADER platform technology is potentially: more resistant to pre-existing immunity than current AAV gene therapies; less immunogenic to enable repeat dosing; and more efficient at gene delivery than other AAV based gene therapies, thus allowing lower dosing.

CureDuchenne Invests In Next Generation Adeno Associated Virus Based Gene Therapy Platform Technology